Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The levels of serum gamma-glutamyl transpeptidase (GGT) and, when appropriate, alkaline phosphatase (AP) and 5'-nucleotidase (NTD) have been measured as a routine in 276 patients with malignant haematological diseases during a 26-month trial period. GGT levels add no prognostic information to the routine haematological surveillance of leukaemia. Polychemotherapy does not appear to be an inducer of liver drug-metabolising microsomal enzymes. Polycythaemia rubra vera, myelofibrosis and chronic lymphocytic leukaemia may cause little change in GGT, AP and NTD levels despite marked hepatomegaly. A raised GGT in Hodgkin's disease and non-Hodgkin lymphoma is generally associated with active and widespread disease, but not necessarily a sign of malignant tissue in the liver. The elevations of GGT in myeloma may be secondary to liver infiltration though this group merits further detailed study.
 ...
PMID:Evaluation of the usefulness of serum gamma-glutamyl transpeptidase levels in the management of haematological neoplasia. 2 19

The number of lymphocytes forming spontaneous rosettes with sheep erythrocytes, a property of thymus-dependent (T) cells, and the number of lymphocytes bearing surface immunoglobulins, a characteristic feature of bone marrow-dependent (B) cells, were determined in the peripheral blood of normals and of patients with chronic lymphocytic leukemia (CLL) and Hodgkin's disease. As compared with normal individuals CLL patients had an increased percentage of lymphocytes with membrane-bound immunoglobulins, whereas the proportion of rosette-forming lymphocytes was reduced. In Hodgkin's disease either normal, diminished, or increased B cell values were obtained; the percentage of T cells was decreased or within the lower range of normals. Lymphocyte transformation by various mitogenic agents in vitro may be regarded as a model of lymphocyte reactivity during immunologic processes in vivo. In order to study the functional capacity of lymphocytes in CLL and Hodgkin's disease in comparison with normal cells, purified peripheral blood lymphocytes from normals and patients with these diseases were incubated in vitro with phytohemagglutinin (PHA) and pokeweed mitogen (PWM) over 7 to 11 days. DNA synthesis was determined by incorporation of 3-H-thymidine. The cyto-architectural features of the cells before and during incubation with these phytomitogens were studied by electron microscopy. Planimetric measurements were performed on micrographs of comparable cell sections (through nucleus and Golgi zone) for the determiniation of cell, nuclear, cytoplasmic, and mitochondrial area. Furthermore, the number of mitochondria and of membrane-bounded acid phosphatase-positive lysosome-like organelles was determined in comparable sections of unstimulated and mitogen transformed lymphocytes.
 ...
PMID:[T and B lymphocytes in chronic lymphocytic leukemia and Hodgkin's disease. Electron microscopic and immunologic studies]. 4 38

In the majority of patients with lympho- and reticulum cell sarcomas, high numbers of B-lymphocytes were found in affected lymph nodes, but were rarely observed in the peripheral blood. In chronic lymphocytic leukaemia receptor properties of B-lymphocytes were defective in several aspects. In patients with Hodgkin's disease the relative number of both lymphocyte populations in the blood were within the normal range and in lymph node suspensions marked alterations were unusual. A preferential proliferation of T-lymphocytes, perhaps accompanied by a reduced life span, was however suggested by double labelling experiments.
 ...
PMID:Classification of malignant lymphomas by means of membrane markers. 5 Jul 9

An increase in the serum copper (Cu++) level has been described as a sensitive index of disease activity in several hematologic and nonhematologic malignancies. In order to explore the diagnostic value of Cu++ compared to other hematochemical parameters frequently abnormal in malignancies, Cu++, serum alpha2 globulin (alpha2), plasmatic fibrinogen (Fibr), the erythrocyte sedimentation rate (ESR), and serum iron (Fe++) have been detected and evaluated in 267 patients affected with the following diseases: Hodgkin's lymphoma (HL), non-Hodgkin's Lymphomas (NHL), Acute Leukemias (AL), Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Myeloma (MM), and Breast Cancer (BC). The best correlation between Cu++ increase and disease activity has been found in HL, NHL, AL, and BC. In these diseases, when the considered parameters were compared, Cu++ and ESR showed a similar pattern, i.e., a high frequency of abnormalities in active disease. It is concluded that Cu++ represents a good complement to some other aspecific parameters in evaluating the activity and diffusion of neoplasias and the therapeutic results, particularly in HL, NHL, AL and BC.
 ...
PMID:The diagnostic value of serum copper levels and other hematochemical parameters in malignancies. 7 79

Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP." Eight patients had prior radiotherapy, included two who had total nodal irradiation. Eight patients (all three with Hodgkin disease and five of eight with non-Hodgkin lymphoma) achieved complete remission (73% of the lymphoma patients). An additional two patients with non-Hodgkin lymphoma sustained partial remissions, for an overall response rate of 91%. Toxicity caused the interruption of therapy in three patients and an additional patient might have sustained a drug-related death. This study compares favorably with other studies investigating primary or secondary combination chemotherapy of advanced lymphomas.
 ...
PMID:A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients. 7 37

Long-term observation of non-Hodgkin's lymphomas indicates they can be sub-divided into two groups with respect to changes in the plasma proteins. The first group has acute phase reactant proteins raised during active disease and sometimes a raised B2m, whilst in remission the protein profile is normal. The second group is typified by a chronic elevation of B2m and ESR but has normal C-RP levels. Chronic lymphocytic leukaemia usually has a raised B2 m level and normal acute phase proteins, a subset with low B2 m is described.
 ...
PMID:Serial measurement of beta2 microglobulin, acute phase reactant proteins and the ESR in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. 8 55

Lysozyme activity was determined in the serum, urine and leukocytes of 53 patients with immunocytoma and 24 patients with lymphoproliferative syndromes without associated monoclonal gammapathy. In patients with multiple myeloma the frequency of low serum lysozyme activity and high leukocyte lysozyme activity was higher. In the cases with renal failure, lysozyme activity was raised in serum and urine, and the 24-hour urinary lysozyme excretion was increased. In 7 patients with increased urinary lysozyme excretion no clinical or laboratory evidence of renal complications was found. Relative monocytosis in peripheral blood was observed in half of the cases of multiple myeloma, and in these patients also in about half of the cases the lysozyme activity was raised in the leukocytes and urine, and the 24-hour urinary lysozyme excretion was increased. In patients with Hodgkin's disease, lymphosarcoma and chronic lymphatic leukemia the frequency of low serum lysozyme activity was increased.
 ...
PMID:Lysozyme in the serum, urine and peripheral blood leukocytes in patients with immunocytoma. 12 34

The aim of the present study is to evaluate the stimulatory capacity of chronic lymphatic leukemia (CLL) and Hodgkin's disease (HD) lymphocytes in the one-way mixed lymphocyte reaction (MLR) and to investigate whether, in patients with these diseases, a correlation exists between the degree of stimulatory capacity and production of a blastogenic factor. These studies might help to resolve the controversy about the nature of the stimulating cells and to offer some insight into the mechanism of the stimulation in the MLR. The significant observations from this study are summarized as follows: (1) Stimulatory capacity of CLL lymphocytes was intact or increased, while their responding capacity was markedly depressed. (2) In our group of patients with advanced Hodgkin's disease, both stimulating and responding capacities were imparied. (3) In these patients a correlation existed between the degree of stimulatory capacity and production of a blastogenic factor. This observation would raise the possibility that the production of a blostogenic factor may in some way be involved in the stimulation of responding lymphocytes in mixed cultures. Our results, which show a dichotomy between MLC stimulatory and responding capacities of CLL lymphocyte, may suggest that different factors are involved in stimulation and response.
 ...
PMID:MLC stimulatory capacity and production of blastogenic factor in patients with chronic lymphatic leukemia and Hodgkin's disease. 12 1

Lymphocyte reactivity in vitro was studied in patients with Hodgkin's disease, chronic lymphocytic leukaemia and lymphosarcoma. The responding capacity to phytohaemagglutinin (PHA) was markedly depressed and delayed in all three groups of patients compared with the PHA response observed in lymphocyte cultures from normal individuals. In one-way mixed lymphocyte culture experiments a significant decrease in responding capacity of the patients' lymphocytes to lymphocytes from normal donors could be demonstrated. In contrast, the stimulatory capacity of the patients' lymphocytes was found to be intact, or only slightly reduced.
 ...
PMID:Mixed lymphocyte culture stimulatory and responding capacity of lymphocytes from patients with lymphoproliferative diseases. 12 26

Proliferative responses by blood and tumor lymphocytes to plant mitogens and allogeneic leukocyte antigens were tested concomitantly on 12 patients with Hodgkin's disease, 10 with chronic lymphocytic leukemia, and seven with non-Hodgkin's lymphomas. In 13 control studies, 3H-thymidine incorporation by blood and lymph node lymphocytes was brisk and, overall, comparable. With Hodgkin's disease, where extent of disease involvement and lymphocyte-depleted tumor histology were factors in the degree of responsiveness, incorporation was higher or at least comparable by tumor lymphocytes when compared with incorporation by autologous blood lymphocytes. Lymph node lymphocytes, especially with clinically stable disease, were more responsive than blood lymphocytes with chronic lymphocytic leukemia. Conversely, tumor lymphocytes were hyporesponsive compared with autologous blood lymphocytes with non-Hodgkin's lymphomas, where prognosis is usually less favorable than with chronic lymphocytic leukemia. Plasma from four out of 33 patients, although not lymphocytotoxic, inhibited lymphoproliferative responses.
 ...
PMID:Reactivity of lymphocytes from primary neoplasms of lymphoid tissues. 13 38


1 2 3 4 5 6 7 8 9 10 Next >>